Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009384 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
A Phase 2 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02009384 is a Phase 2 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 2 participants.
The verdict
NCT02009384, a Phase 2 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will be enrolled and treated in the study.
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009384
The ClinicalTrials.gov registry entry for NCT02009384 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT02009384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009384 about?
NCT02009384 is a clinical study titled "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox". This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will...
What is the current status of trial NCT02009384?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02009384?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02009384?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.